REYKJAVIK, Iceland, Aug. 28 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced that it will host a live webcast of deCODE CSO Jeffrey Gulcher's presentation at Thomas Weisel Partners Healthcare Conference 2008.
The presentation will be delivered at 1:30 PM ET / 5:30 PM GMT / 6:30 PM British Summer Time on Wednesday, September 3 at the Four Seasons Hotel, Boston, MA. The webcast can be accessed through the Investors page on deCODE's website, http://www.decode.com, and those interested in listening should log on a few minutes in advance in order to download any software or complete any sign-in that may be required. The webcast will be archived for at least one week.
deCODE is a biopharmaceutical company applying its discoveries in human
genetics to the development of diagnostics and drugs for common diseases.
deCODE is a global leader in gene discovery -- our population approach and
resources have enabled us to isolate key genes contributing to major public
health challenges from cardiovascular disease to cancer, genes that are
providing us with drug targets rooted in the basic biology of disease.
Through its CLIA-registered laboratory, deCODE is offering a growing range
of DNA-based tests for gauging risk and empowering prevention of common
diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for
atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE
ProCa(TM) for prostate cancer; and deCODE Glaucoma(TM) for a major type of
glaucoma. deCODE is delivering on the promise of the new genetics(SM).
Visit us on the web at http://www.decode.com; on our diagnostics website at
http://www.decodediagnostics.com; and, for our pioneering personal genome analysis
service, at http://www.decodeme.com.
|SOURCE deCODE genetics|
Copyright©2008 PR Newswire.
All rights reserved